Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | PNMT | P11086 | 6/20 | 0.48 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1265678 | 0.98 | ASIC3 (0.53) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL7921103 | 0.93 | PNMT (0.55) | DRD2DRD3PNMTCD44MAOB | |
| SCHEMBL19185632 | 0.89 | ASIC3 (0.43) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL20892189 | 0.89 | HTR2C (0.52) | ASIC3DRD2PNMTADRA2AADRA2B | |
| SCHEMBL3243076 | 0.86 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL3055999 | 0.86 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL18717400 | 0.86 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL3247113 | 0.86 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL17585071 | 0.85 | ASIC3 (0.55) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL2736425 | 0.84 | CHRNB2 (0.42) | ASIC3PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023205507-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-7879876-B2 | matrix metalloproteinase inhibitors such as N-{1-[(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)methyl]-3-phenylpropyl}-N-hydroxy formamide; prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular disorders, neurodegenerative diseases, cancer, respiratory system disorders and fibrosis | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | LABORATOIRES SERONO SA (CH) | 2009-09-03 | — | — | US | disclosed |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | LABORATOIRES SERONO SA (CH) | 2009-09-03 | — | — | US | disclosed |
| WO-2009047240-A1 | INDOLE DERIVATIVES USEFUL AS PPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047240-A1 | INDOLE DERIVATIVES USEFUL AS PPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2007048788-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | LABORATOIRES SERONO S.A. (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | ASIC3 3048/4885DRD2 4223/4885DRD3 3578/4885 |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | ASIC3 4271/4885DRD2 2886/4885DRD3 3015/4885 |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F8, F9 | ASIC3 3479/4885DRD2 4295/4885DRD3 3666/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ASIC3 505/4885DRD2 4505/4885DRD3 4541/4885 |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | MMP12, STS, MMP14 | ASIC3 2312/4885DRD2 4790/4885DRD3 4779/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | ASIC3 4614/4885DRD2 4688/4885DRD3 4662/4885 |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F5 | ASIC3 4284/4885DRD2 1117/4885DRD3 659/4885 |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, SHBG, NR5A1 | ASIC3 2695/4885DRD2 1120/4885DRD3 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.